Clovis Oncology, Inc. (CLVSQ) vs Cerenome, Inc. (CNSY)

Clovis Oncology, Inc. and Cerenome, Inc. are both Biotechnology companies. Clovis Oncology, Inc. and Cerenome, Inc. are of similar size ($14.3M and $14.2M). Clovis Oncology, Inc. grew revenue faster over the last twelve months: −14.8% against −21.0%. Clovis Oncology, Inc. has the higher net margin (−189.4% vs −526.5%) and the higher return on invested capital (0.00% vs −532.8%). Across the 17 metrics below, Clovis Oncology, Inc. leads on 11 and Cerenome, Inc. on 6.

Valuation

Metric CLVSQ CNSY Biotechnology median
P/E n/m n/m 7.88
P/S 0.10 3.27 11.47
P/B n/m 2.51 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 3.08 2.89 10.73
Earnings yield (2,033.33%) (168.84%) (28.84%)
Free cash flow yield (1,412.40%) (175.55%) (23.03%)

Profitability

Metric CLVSQ CNSY Biotechnology median
Gross margin 72.21% 100.00% 65.16%
Operating margin (155.38%) (628.12%) 0.00%
Net margin (189.37%) (526.48%) 0.00%
Free cash flow margin (132.19%) (560.29%) 0.00%
Return on equity 78.31% (520.84%) (57.72%)
Return on assets (58.94%) (181.53%) (49.22%)
Return on invested capital 0.00% (532.77%) 0.00%

Growth

Metric CLVSQ CNSY Biotechnology median
Revenue growth (TTM) (14.78%) (20.95%) 5.64%
EPS growth (last fiscal year) 47.72% 82.79% —
Revenue growth, 5-year CAGR 352.98% (5.72%) 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CLVSQ CNSY Biotechnology median
Debt to equity (1.09) 0.00 0.00
Current ratio 0.14 1.37 4.73
Net debt to EBITDA (2.21) 0.83 0.96

Dividend

Metric CLVSQ CNSY Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric CLVSQ CNSY Biotechnology median
Market cap 14.23m 14.26m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack